Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospira, Inc.

http://www.hospira.com

Latest From Hospira, Inc.

Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds

Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.

Financing Innovation

Baxter: If Your Lips Turn Blue, Stop Using Our Device

Baxter Healthcare says there’s a risk of decreased oxygen levels or lung over-expansion when using its Volara System “in line with a ventilator.” The firm launched a recall of the device on 1 June.

Recalls Safety

Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

Tech Transfer Round-Up Deals

A Tricky Outlook, But Medtech Has Opportunities To Grow

In Vivo editorial advisory board member and ZS principal Brian Chapman identifies the agenda-topping themes for medtech bosses.

Strategy Growth
See All

Company Information

  • Other Names / Subsidiaries
    • Javelin Pharmaceuticals, Inc.
    • Mayne Pharma Limited
UsernamePublicRestriction

Register